Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP

Executive Summary

Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.
Advertisement

Related Content

Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
With Strong Q3 Financials, Pfizer Says It's Ready For Generic Competition To Lipitor
Cost-Effectiveness Colors ACIP Decision On Hep B Vaccination For Diabetics
Cost-Effectiveness Colors ACIP Decision On Hep B Vaccination For Diabetics
Cost-Effectiveness Colors ACIP Decision On Hep B Vaccination For Diabetics
Prevnar 13 Advisory Committee Review Moved Back To November

Topics

Advertisement
UsernamePublicRestriction

Register

PS053898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel